USD
GBP 
CNY 
EUR 
INR 
JPY 
MYR 
ZAR 
KRW 
THB 
Emerging Therapeutics for Neurodegenerative Diseases, Global, 2025-2030
Innovative Strategies Driving the Future of Neuro Diseases
19-Aug-2025
Global
Market Research
DB2D-01-00-00-00
HC_2025_33736
This report is a thorough examination of the current and future face of therapy for neurodegenerative diseases, such as Alzheimer's and Parkinson's. It articulates important growth drivers (e.g., precision medicine, AI paradigm for diagnostics, and the transformational megatrends of aging populations) and barriers they will face (e.g., the nature of competition and geopolitical upheaval).
The report will examine emerging therapeutic modalities including biologics (monoclonal antibodies and nucleic acid therapies), small molecules (amyloidogenesis inhibitors and NMDA antagonists), and alternative therapies (clinical nutraceuticals and microbiome). It also examines essential strategies such as convergence and disruption, as well as pipeline reviews of major emerging drugs and devices from prominent academic and industry participants. It pinpoints high-growth opportunities, such as disease-modifying therapies, immunotherapy drug products, and precision medicine along with funding trends and collaborations with strategic partners.
The study integrates technological, clinical, and market trends to provide actionable recommendations to stakeholders and emphasize the high-growth, multitrillion-dollar opportunities in the emerging neurodegenerative therapeutics space.
Why Is It Increasingly Difficult to Grow?
The Strategic Imperative 8
The Impact of the Top 3 Strategic Imperatives on Emerging Therapeutics for Neurodegenerative Diseases
Growth Opportunities Fuel the Growth Pipeline Engine
Research Methodology
Scope of Analysis
Segmentation
Growth Drivers
Growth Restraints
Neurodegenerative Diseases: Facts and Challenges
Understanding the Most Prevalent and Impactful Disorders of the Aging Brain
Alzheimer’s and Parkinson’s Diseases Are the Leading Neurodegenerative Disorders
Neurodegenerative Diseases: Emerging Therapies Under Biologics
Mechanism and Clinical Applications: Nucleic Acid Therapies
Mechanism and Clinical Applications: Monoclonal Antibodies
Mechanism and Clinical Applications: Microbiome-Based Therapies
Neurodegenerative Diseases: Emerging Therapies Under Small Molecules
Mechanism and Clinical Applications: Amyloidogenesis Inhibitors
Mechanism and Clinical Applications: NMDA Receptor Antagonist
Mechanism and Clinical Applications: Cholinesterase Inhibitors
Neurodegenerative Diseases: Alternative Therapies
Mechanism and Clinical Applications: Nutraceuticals
Mechanism and Clinical Applications: Ayurvedic and Traditional Practices
Clinical Pipeline Overview for Alzheimer's
Clinical Pipeline Innovator Profiles
Clinical Pipeline Overview for Parkinson’s
Clinical Pipeline Innovator Profiles
Funding Analysis
Key Partnerships and Acquisitions
Innovative Biologic Delivery Systems Outlook
Target-Specific Monoclonal Antibodies Outlook
Gene Therapy and Genetic Engineering Outlook
Growth Opportunity 1: Advancements in Precision Medicine and Personalized Therapies
Growth Opportunity 2: Breakthroughs in Disease-Modifying Therapies
Growth Opportunity 3: Advancing Immunotherapeutic Approaches
Benefits and Impacts of Growth Opportunities
Next Steps
Legal Disclaimer
Speak directly with our analytics experts for tailored recommendations.
Recent related Pharmaceuticals research
31 Jul 2026 | Global | Market Research
Growth Opportunities in Small-Molecule Contract Development and Manufacturing Organizations, Global, 2026–2031
The global small‑molecule CDMO industry is undergoing a structural transformation driven by increasing molecular complexity, patent expiries, cost pressures, and the strategic need to secure resilient pharmaceutical supply chains. Demand is shifting beyond high‑volume commodity generics toward s...
30 Jul 2026 | Global | Frost Radar
Frost Radar™: Life Sciences Regulatory Information Management Platforms, 2026
The regulatory technology market in life sciences has, over the last five years, quietly transformed from a back-office category dominated by document repositories and submission publishing tools to one of the most consequential software segments serving the pharmaceutical, biotech, and medical devi...
17 Jul 2026 | Global | Technology Research
Innovations and Growth Opportunities in AI-Driven Drug Discovery, Precision Diagnostics, Advanced Biologics, and Next-generation Vaccines
This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides a comprehensive overview of breakthrough innovations reshaping drug discovery, diagnostics, and therapeutic delivery across oncology, infectious diseases, rare and autoimmune disorders, metabolic and age...
13 Jul 2026 | Global | Technology Research
RNA Therapies in Rare Diseases
Rare diseases pose a global burden to healthcare despite making up a very small fraction of the global disease landscape. Most treatment options for rare diseases focus on maintaining the disease symptoms, rather than a disease-modifying approach. To address this unmet need, RNA therapies are emergi...
08 Jul 2026 | Global | Technology Research
Precision Obesity Management: AI-Guided Metabolic Modulation
The report explores the transformation of obesity care from generalized BMI-based treatment to AI-enabled precision metabolic management. The study highlights how obesity is increasingly recognized as a heterogeneous, multi-pathway disease influenced by genetic, neurobehavioral, metabolic, and envir...
Purchase includes:
- Report download
- Growth Dialog™ with our experts
Growth Dialog™
A tailored session with you where we identify the:- Strategic Imperatives
- Growth Opportunities
- Best Practices
- Companies to Action
Impacting your company's future growth potential.
The report will examine emerging therapeutic modalities including biologics (monoclonal antibodies and nucleic acid therapies), small molecules (amyloidogenesis inhibitors and NMDA antagonists), and alternative therapies (clinical nutraceuticals and microbiome). It also examines essential strategies such as convergence and disruption, as well as pipeline reviews of major emerging drugs and devices from prominent academic and industry participants. It pinpoints high-growth opportunities, such as disease-modifying therapies, immunotherapy drug products, and precision medicine along with funding trends and collaborations with strategic partners.
The study integrates technological, clinical, and market trends to provide actionable recommendations to stakeholders and emphasize the high-growth, multitrillion-dollar opportunities in the emerging neurodegenerative therapeutics space.
| Deliverable Type | Market Research |
|---|---|
| Industries | Healthcare |
| No Index | No |
| Is Prebook | No |
| Keyword 1 | Neurodegenerative Disease Market |
| Keyword 2 | neurodegenerative disease drug development |
| Keyword 3 | clinical pipeline innovation neurology |
| Podcast | No |
| Predecessor | None |
| WIP Number | DB2D-01-00-00-00 |